China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Want to cut your energy bills? Here’s how five experts are doing it 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
NEW YORK, May 25, 2017 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of ImmunoCellular Therapeutics, Ltd. (NYSE MKT:IMUC) who purchased shares between May 1, 2012 and December 11, 2013. The action, which was filed in the United States District Court for the Central District of California, alleges that the Company violated federal securities laws.
In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that (1) ImmunoCellular retained Lidingo Holdings, LLC to publish promotional articles designed to unlawfully promote the Company; (2) as a result of this scheme, the market was led to believe that ImmunoCellular's clinical studies for its product candidate ICT-107 was going well and the Company's share price was artificially inflated.
On April 10, 2017, the Securities and Exchange Commission announced enforcement actions against numerous individuals and entities, including ImmunoCellular, that had engaged in stock promotion schemes.
Shareholders have until June 30, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sa/immunocellular-therapeutics-ltd?wire=1.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th Floor New York, NY 10118 Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com
